Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4895]

SABCS 2016: Adding an aromatase inhibitor to presurgery treatment for HR/HER2 positive breast cancer provided no additional benefit

SABCS 2016: Adding an aromatase inhibitor to presurgery treatment for HR/HER2 positive breast cancer provided no...

Personalised cancer vaccine associated with promising outcomes for AML patients

Personalised cancer vaccine associated with promising outcomes for AML patients

SABCS 2016 : Adding veliparib to chemotherapy improved response rates among patients with BRCA-mutant breast cancer

SABCS 2016 : Adding veliparib to chemotherapy improved response rates among patients with BRCA-mutant breast cancer

SABCS 2016: Extended letrozole therapy showed limited benefit in postmenopausal women with early-stage, HR-positive breast cancer

SABCS 2016: Extended letrozole therapy showed limited benefit in postmenopausal women with early-stage, HR...

SABCS 2016: Genomic sequencing of treatment-resistant metastatic breast cancer reveals clinically relevant genetic alterations

SABCS 2016: Genomic sequencing of treatment-resistant metastatic breast cancer reveals clinically relevant genetic...

ASH 2016: Additions to standard multiple myeloma therapy do not appear to yield additional benefit

ASH 2016: Additions to standard multiple myeloma therapy do not appear to yield additional benefit

ASH 2016: IKZF1 mutations found to increase hereditary risk for ALL in children

ASH 2016: IKZF1 mutations found to increase hereditary risk for ALL in children

ASH 2016: Nivolumab with chemotherapy improves response, survival in AML study patients

ASH 2016: Nivolumab with chemotherapy improves response, survival in AML study patients

ASH 2016 : Reducing or stopping TKI for CML can be safe, beneficial for some patients

ASH 2016 : Reducing or stopping TKI for CML can be safe, beneficial for some patients

ASH 2016: New CAR-T treatment holds promise for children and young adults with hard-to-treat leukaemia

ASH 2016: New CAR-T treatment holds promise for children and young adults with hard-to-treat leukaemia

More from ecancer